Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

DeFi Crypto Mutuum Finance Confirms Q4 2025 V1 Launch as MUTM Surges 250% with Phase 6 Over 95%

December 12, 2025

GXO Appoints Bart Beeks as Chief Operating Officer

December 12, 2025

Koryx Copper Announces Further Positive Drill Results at the Haib Copper Project, Southern Namibia

December 12, 2025

Serve Robotics Builds 2,000 Autonomous Delivery Robots, Creating Largest Sidewalk Delivery Fleet in the U.S.

December 12, 2025

Mutuum Finance (MUTM) V1 Launch Readiness Update Signals Strong Technical Progress With Over $19M in Funding

December 12, 2025
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Autoimmune Disease Diagnosis Market to Surge to USD 8.98 Billion by 2031
Press Release

Autoimmune Disease Diagnosis Market to Surge to USD 8.98 Billion by 2031

By News RoomDecember 12, 20254 Mins Read
Autoimmune Disease Diagnosis Market to Surge to USD 8.98 Billion by 2031
Share
Facebook Twitter LinkedIn Pinterest Email
Autoimmune Disease Diagnosis Market to Surge to USD 8.98 Billion by 2031

Dublin, Dec. 12, 2025 (GLOBE NEWSWIRE) — The “Autoimmunity Diagnostics Market by Product (Consumables, Instruments), Test Type (Routine, Autoantibody, Inflammatory, Urinalysis Tests), Disease (RA, SLE, MS, IBD), End User (Clinical Laboratories, Hospitals & Clinics) – Global Forecast to 2031” has been added to ResearchAndMarkets.com’s offering.

The autoimmune disease diagnosis market is projected to reach USD 8.98 billion by 2031, up from USD 5.57 billion in 2025, marking a compound annual growth rate (CAGR) of 8.3% over the forecast period. Key drivers include a rise in autoimmune disorders, enhanced awareness of early diagnoses, and technological advancements such as multiplex immunoassays and biomarker-based tests. Moreover, the adoption of automated platforms and supportive government policies are promoting increased testing volumes and enhancing diagnostic precision.

By disease type, the systemic autoimmune diseases segment led the market in 2024. Globally, the autoimmune disease diagnosis market divides into systemic and organ-specific autoimmune diseases. Systemic autoimmune diseases held the largest market share in 2024 due to the high prevalence of conditions like rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. These conditions often impact multiple organs, necessitating comprehensive diagnostic evaluations. The complex nature of these diagnoses, dependence on advanced immunological tests, and continuous monitoring fuel demand for diagnostic solutions in this segment.

By end user, clinical laboratories dominated the market during the forecast period. The market is segmented into clinical laboratories, hospitals & clinics, and other end users. Clinical laboratories emerged as the largest market share holder due to their specialized expertise, advanced diagnostic technologies, and high-throughput capabilities. These labs utilize automated platforms, including ELISA, chemiluminescence, and immunofluorescence, to conduct complex tests efficiently. Their role as centralized hubs allows for processing large sample volumes cost-effectively.

Asia Pacific: The fastest-growing region in the autoimmune disease diagnosis market during the forecast period. Regionally, the market segments into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is poised to grow the fastest, driven by a rise in autoimmune diseases, increasing healthcare expenditure, and adoption of advanced diagnostics. Additionally, improved healthcare infrastructure and governmental initiatives are bolstering market growth in the Asia Pacific.

Breakdown of primary participants in the autoimmune disease diagnosis market:

  • By Company Type: Tier 1 – 40%, Tier 2 – 30%, Tier 3 – 30%
  • By Designation: C-level – 27%, D-level – 18%, Others – 55%
  • By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, Middle East & Africa – 4%

Leading market players include Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), and Grifols S.A. (Spain), among others.

Research Coverage: The report categorizes the autoimmune disease diagnosis market by product, test type, disease type, end user, and region. It provides detailed insights into significant factors like drivers, restraints, opportunities, and challenges impacting market growth. A comprehensive analysis of key industry players, including their business overview, key strategies, acquisitions, and new product launches, is featured. Furthermore, the report examines the competitive landscape, focusing on upcoming startups within the ecosystem.

Reasons to buy this report: The report assists market leaders and entrants in understanding revenue projections for the autoimmune disease diagnosis market and its subsegments. Stakeholders gain insights into the competitive landscape, enhancing their ability to position businesses strategically and plan effective go-to-market approaches. Additionally, insights into key market drivers, restraints, opportunities, and challenges are provided.

The report provides insights on the following pointers:

  • Analysis of key drivers, such as the high incidence of autoimmune diseases and advancements in diagnostic technologies; restraints like high capital needs; opportunities including biosensor utilization; and challenges like diagnosis complexities and lack of skilled professionals.
  • Product Development/Innovation: Insights on new technologies, R&D activities, and product launches.
  • Market Development: Analysis of lucrative markets across different regions.
  • Market Diversification: Information on new products and recent developments.
  • Competitive Assessment: In-depth analysis of market shares and strategies of leading players such as F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Revvity, Inc. (US), and Thermo Fisher Scientific Inc. (US).

Key Attributes:

Report Attribute Details
No. of Pages 299
Forecast Period 2025 – 2031
Estimated Market Value (USD) in 2025 $5.57 Billion
Forecasted Market Value (USD) by 2031 $8.98 Billion
Compound Annual Growth Rate 8.3%
Regions Covered Global

Company Profiles

  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Revvity, Inc.
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • Bio-Rad Laboratories, Inc.
  • Grifols SA
  • Werfen SA
  • Exagen Inc.
  • Trinity Biotech PLC
  • Tecan Group Ltd.
  • Danaher Corporation
  • Biosynex SA
  • Quidelortho Corporation
  • Biomerieux SA
  • Diasorin S.P.A.
  • Becton, Dickinson and Company
  • Sd Biosensor, Inc.
  • Cambridge Life Sciences Ltd.
  • A. Menarini Diagnostics S.R.L
  • Sebia
  • Kronus
  • Erba Group
  • Aesku.Group GmbH
  • Medsource Ozone Biomedicals Pvt. Ltd.
  • Epitope Diagnostics Inc.

For more information about this report visit https://www.researchandmarkets.com/r/ywaszr

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Autoimmunity Diagnostics Market

            
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

DeFi Crypto Mutuum Finance Confirms Q4 2025 V1 Launch as MUTM Surges 250% with Phase 6 Over 95%

GXO Appoints Bart Beeks as Chief Operating Officer

Koryx Copper Announces Further Positive Drill Results at the Haib Copper Project, Southern Namibia

Serve Robotics Builds 2,000 Autonomous Delivery Robots, Creating Largest Sidewalk Delivery Fleet in the U.S.

Mutuum Finance (MUTM) V1 Launch Readiness Update Signals Strong Technical Progress With Over $19M in Funding

45 MoUs Valued at SAR 6 Billion Signed at MOMENTUM 2025 to Power Saudi Arabia’s Sustainable Development

Novartis breaks ground on flagship manufacturing hub in North Carolina

SciChart strengthens its role in F1 Data Visualization as the sport’s software-driven engineering demands intensify

RentRedi Launches AI-powered Accounting Suite

Editors Picks

GXO Appoints Bart Beeks as Chief Operating Officer

December 12, 2025

Koryx Copper Announces Further Positive Drill Results at the Haib Copper Project, Southern Namibia

December 12, 2025

Serve Robotics Builds 2,000 Autonomous Delivery Robots, Creating Largest Sidewalk Delivery Fleet in the U.S.

December 12, 2025

Mutuum Finance (MUTM) V1 Launch Readiness Update Signals Strong Technical Progress With Over $19M in Funding

December 12, 2025

Subscribe to News

Get the latest Canada news and updates directly to your inbox.

Latest News

45 MoUs Valued at SAR 6 Billion Signed at MOMENTUM 2025 to Power Saudi Arabia’s Sustainable Development

December 12, 2025

My defense of a $40 cable paperweight – I’m sorry

December 12, 2025

Novartis breaks ground on flagship manufacturing hub in North Carolina

December 12, 2025
Facebook X (Twitter) Pinterest TikTok Instagram
© 2025 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version